pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
amunix PRESS RELEASE ARCHIVE
Dec 20, 2021
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle
Oct 7, 2021
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
Jun 23, 2021
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
Apr 12, 2021
Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety
Jan 26, 2021
Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors
Dec 9, 2020
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020
Jun 22, 2020
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
May 27, 2020
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
Jan 10, 2020
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
Jun 26, 2019
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
May 14, 2019
Amunix Expands Executive Team with Appointment of Dr. Mika Derynck as CMO, Dr. Darcy Mootz as CBO, and Yvonne Li as SVP of Finance
Jan 3, 2019
Amunix Announces Licensing Agreement with Merck for ProTIA Immune Activator Platform
Jan 3, 2019
Amunix Announces Appointment of Dr. Angie You as Chief Executive Officer and Dr. Rich Heyman as Chairman of the Board of Directors
May 29, 2018
Amunix announces report by Bioverativ on unprecedented half-life obtained in patients treated with a novel, long-acting FVIII utilizing Amunix’s XTEN technology
Feb 20, 2018
Amunix announces XTEN and ProTIA technology licensing agreement with Celgene
Feb 13, 2018
Amunix CEO to deliver keynote address on ProTIA, Amunix’s novel immuno-oncology technology, at the Biologics and Biosimilars Congress Europe (March 2018)
Jan 21, 2013
Amunix Announces Licensing Agreement For Its Proprietary XTEN Technology
